Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07643623 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Name: Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma — clinical trial record (NCT07643623)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2/3

SponsorInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Started2026-07-31

View on ClinicalTrials.gov ↗

Amendment history

2026-08-12

Study Status, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-06-15→confirmed 2026-07-31

Study sitesdetails revised at 1 of 1 site

2026-06-09

Original filing

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

7 trials monitored

See 1 trial at risk

This is a Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined with Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma.

Trial Details

NCT Number	NCT07643623
Lead Sponsor	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Conditions	Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Enrollment	720 participants
Start Date	2026-07-31
Primary Completion	2031-12-31 (estimated)
Study Completion	2031-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-14